Content overview: “Hims & Hers to Offer Testosterone Replacement Therapy, Entering Controlled Substance Marke”. Telehealth company Hims & Hers is expanding into testosterone replacement therapy (TRT), a move that marks its first foray into prescribing controlled substances. The company, known for its direct-to-consumer treatments for hair loss, erectile dysfunction, and mental health, will now offer at-home testosterone testing and, if indicated, TRT. This expansion taps into the growing men's health market, where low testosterone is increasingly diagnosed and treated, though not without controversy.
Hims & Hers plans to leverage its existing telehealth platform to streamline the process, potentially reaching millions of men who may not have sought treatment through traditional channels. The company's stock has seen significant growth, and this new offering could further boost its position in the competitive telehealth space. However, the move also raises questions about the medicalization of aging and the risks of overprescribing testosterone, which is a Schedule III controlled substance. This listing links straight to the original page, where the content is available in full.